According to reports from Business Standard, Amanta Healthcare reported a 5.70% decline in standalone net profit to ₹3.31 crore in the quarter ended June 2026, compared to ₹3.51 crore in the corresponding quarter of the previous year. Despite the profit decline, the company demonstrated revenue growth with sales rising 5.34% to ₹68.80 crore in Q1 FY2026-27, up from ₹65.31 crore in Q1 FY2025-26. The company's operating profit margin (OPM) improved to 21.13% in the June 2026 quarter, compared to 22.81% in the same quarter of the previous year, though this represented a 168 basis points contraction due to inflationary cost pressures during the transition phase.
As reported by Business Standard, the company's operating profit margin (OPM) improved to 21.13% in the June 2026 quarter, compared to 22.81% in the same quarter of the previous year. However, PBDT (Profit Before Depreciation and Tax) declined 4% to ₹9.18 crore from ₹9.57 crore year-on-year. The profit before tax (PBT) also fell 9% to ₹4.49 crore compared to ₹4.93 crore in the corresponding quarter of FY2025-26. Operating EBITDA stood at ₹14.5 crore, down 2.68% year-on-year from ₹14.9 crore, while revenue declined QoQ to ₹68.8 crore from ₹77.0 crore in Q4 FY6. The net profit decline was primarily driven by higher finance costs associated with the new Solar Term Loan, which impacted overall profitability despite operational resilience.
According to latest market data from Choice, Amanta Healthcare shares are currently trading at ₹169.54 as of August 6, 2026, with a market capitalization of ₹388.29 crore. The stock has shown 52-week high of ₹189.00 and 52-week low of ₹92.00, indicating significant price volatility. Trading activity recorded 6,020 shares with an Average Traded Price (ATP) of ₹169.54. The stock operates under No framework with a market lot size of ₹1, and the upper circuit limit is ₹176.46 and lower circuit limit is ₹169.54. The Delivery Percentage for the day is 0%, reflecting current trading conditions.
